Scientific Sessions 2025  /  Translating Data into Outcomes in Critical Care  /  Leveraging the AHA cardiogenic shock registry to perform pragmatic clinical trials
Logo

American Heart Association

  36
  0

Final ID:

Leveraging the AHA cardiogenic shock registry to perform pragmatic clinical trials

  • Morrow, David  ( BWH , Boston , Massachusetts , United States )
  • Berg, David  ( Brigham and Womens Hospital , Boston , Massachusetts , United States )
    • Author Disclosures:
    David Morrow: DO have relevant financial relationships ; Research Funding (PI or named investigator):Abbott:Active (exists now) ; Consultant:Roche:Active (exists now) ; Consultant:Regeneron:Active (exists now) ; Consultant:Merck & Co:Active (exists now) ; Consultant:Abbott:Past (completed) ; Research Funding (PI or named investigator):Roche:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Research Funding (PI or named investigator):Novartis:Active (exists now) ; Research Funding (PI or named investigator):Merck & Co:Active (exists now) ; Research Funding (PI or named investigator):4TEEN4:Active (exists now) ; Research Funding (PI or named investigator):Daiichi-Sankyo:Active (exists now) ; Research Funding (PI or named investigator):AstraZeneca:Active (exists now) ; Research Funding (PI or named investigator):Anthos Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):Amgen:Active (exists now) ; Research Funding (PI or named investigator):Abiomed:Active (exists now) | David Berg: DO have relevant financial relationships ; Research Funding (PI or named investigator):AstraZenea:Active (exists now) ; Other (please indicate in the box next to the company name):CEC - CeleCor Therapeutics:Active (exists now) ; Other (please indicate in the box next to the company name):CEC - Beckman Coulter:Active (exists now) ; Other (please indicate in the box next to the company name):CEC - Novo Nordisk:Active (exists now) ; Other (please indicate in the box next to the company name):CEC - Tosoh Biosciences:Active (exists now) ; Other (please indicate in the box next to the company name):CEC - Kowa Pharmaceuticals:Past (completed) ; Speaker:USV Private Limited:Past (completed) ; Speaker:Pri-Med:Past (completed) ; Speaker:Metabolic Endocrine Education Foundation:Past (completed) ; Consultant:Youngene Therapeutics:Past (completed) ; Consultant:Pfizer:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Research Funding (PI or named investigator):Merck:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Translating Data into Outcomes in Critical Care

Friday, 11/07/2025 , 02:15PM - 03:30PM

Cardiovascular Seminar

More abstracts on this topic:
Biomarkers in cardiogenic shock: but isn't lactic acide enough?

O'brien Connor, Park Ashley

Relieving the pressure: Unloading the left ventricle in cardiogenic shock

Ardissino Maddalena, Soeholm Helle

More abstracts from these authors:
Mechanical Circulatory Support Device Related Complications in Contemporary North American Cardiac Intensive Care Units

Kochar Ajar, Park Jeong-gun, Berg David, Patel Siddharth, Bohula Erin, Morrow David

Association between Pressure-Adjusted Heart Rate and Mortality in Cardiogenic Shock

Ginder Curtis, Jentzer Jacob, Guo Jianping, Van Diepen Sean, Katz Jason, Morrow David, Berg David

You have to be authorized to contact abstract author. Please, Login
Not Available